Skip to content
CancerIndex

Publication

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Authors not recorded

Nature2012PMID 22281684stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (6)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 6

Curated evidence

Evidence citing this paper (3)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
22281684
Run
ING-CIVIC-20260908-000001
Open at source CuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
BRAF V600E3
VemurafenibMalignant Colorectal NeoplasmCURATED_BROADERPredictiveDSupports Resistance3submitted
EID10329

Five colorectal cancer (CRC) cell lines (VACO432, HT29, SNU-C5, KM20, WiDr) with BRAF V600E mutation were resistant to treatment with the BRAF inhibitor vemurafenib. An RNAi screen in the WiDr cell li… (full text at CIViC)

PMID 22281684 · Prahallad et al., 2012 · Open in CIViC

civic
Gefitinib + VemurafenibCombinationMalignant Colorectal NeoplasmCURATED_BROADERPredictiveDSupports Sensitivity Response3submitted
EID10328

Five colorectal cancer (CRC) cell lines with BRAF V600E mutation were resistant to treatment with the BRAF inhibitor vemurafenib. An RNAi screen in the WiDr cell line (a V600E CRC line) identified EGF… (full text at CIViC)

PMID 22281684 · Prahallad et al., 2012 · Open in CIViC

civic
Cetuximab + Gefitinib + VemurafenibCombinationMalignant Colorectal NeoplasmCURATED_BROADERPredictiveDSupports Sensitivity Response3accepted
EID1408

5 of 7 colorectal cancer (CRC) cell lines with BRAF V600E mutation were resistant to treatment with the BRAF inhibitor vemurafenib. An RNAi screen in the WiDr cell line (a V600E CRC line) identified E… (full text at CIViC)

PMID 22281684 · Prahallad et al., 2012 · Open in CIViC

civic